Patent ID: 11970533
Assignee: SPARX BIOSCIENCE LIMITED
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 1:
2. The bispecific antibody of claim 1, wherein the second antigen-binding moiety that binds human PD-L1 comprises:
(a) a second VH, which comprises the same heavy chain complementarity-determining regions (CDRs) as a reference anti-human PD-L1 antibody; and
(b) a second light chain variable domain (VL), which comprises the same light chain CDRs as the reference anti-human PD-L1 antibody; and
wherein the reference anti-human PD-L1 antibody is selected from the group consisting of durvalumab, atezolizumab, avelumab, and an 12A4 antibody, wherein the 12A4 antibody has a heavy chain and a light chain comprising the following amino acid sequences, respectively:
(1) SEQ ID NOs: 285 and 281,
(2) SEQ ID NOs: 308 and 309,
(3) SEQ ID NOs: 310 and 311,
(4) SEQ ID NOs: 312 and 313,
(5) SEQ ID NOs: 314 and 315,
(6) SEQ ID NOs: 316 and 317,
(7) SEQ ID NOs: 318 and 319,
(8) SEQ ID NOs: 320 and 321,
(9) SEQ ID NOs: 322 and 323,
(10) SEQ ID NOs: 324 and 325,
(11) SEQ ID NOs: 326 and 327,
(12) SEQ ID NOs: 328 and 329,
(13) SEQ ID NOs: 330 and 331, or
(14) SEQ ID NOs: 293 and 291.